ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
stockNASDAQ
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx's lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 13.34 | 2026-10-27 | -3.15% | -1.759 |
| 1M | 15.51 | 2026-10-02 | -16.70% | 0.770 |
| 3M | 18.45 | 2026-08-03 | -29.97% | -0.445 |
| 6M | 0.18 | 2026-05-04 | +7081.77% | 57.561 |
| 1Y | 0.00 | 2025-10-31 | +12919900.00% | 582.949 |
| 2Y | 0.00 | 2024-11-04 | +6459900.00% | — |
| 5Y | 58.00 | 2021-11-03 | -77.72% | 78.677 |
Eloxx Pharmaceuticals, Inc. Common Stock (NASDAQ:ELOX) stock price today is $12.92, and today's volume is 20,214. ELOX is up 0.623% today. The 30 day average volume is 24,212. ELOX market cap is $52.15M with 4.04M shares outstanding.